BELSOMRA Drug Patent Profile

When do Belsomra patents expire, and what generic alternatives are available?

Belsomra is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-five patent family members in thirty-six countries.

The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this compound. Additional details are available on the suvorexant profile page.

DrugPatentWatch^® Generic Entry Outlook for Belsomra

Belsomra was eligible for patent challenges on August 13, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 29, 2033. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

There is one tentative approval for the generic drug (suvorexant), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for BELSOMRA

International Patents:	75
US Patents:	3
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for BELSOMRA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BELSOMRA	Tablets	suvorexant	5 mg, 10 mg, 15 mg and 20 mg	204569	1	2024-03-04

US Patents and Regulatory Information for BELSOMRA

BELSOMRA is protected by three US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-001	Aug 13, 2014		RX	Yes	No			Y	Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-003	Aug 13, 2014		RX	Yes	No			Y	Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-002	Aug 13, 2014		RX	Yes	No			Y	Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-004	Aug 13, 2014		RX	Yes	Yes			Y

International Patents for BELSOMRA

When does loss-of-exclusivity occur for BELSOMRA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Japan

Mexico

Russian Federation

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BELSOMRA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2007328267
Russian Federation	2561727
Brazil	112014025041	composição farmacêutica
Mexico	368859	FORMULACIONES DE DOSIS SOLIDA DE UN ANTAGONISTA DEL RECEPTOR DE OREXINA. (SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST.)

BELSOMRA (Suvorexant) Patent Landscape and Investment Outlook

Last updated: February 19, 2026

BELSOMRA, the oral orexin receptor antagonist developed by Merck & Co., Inc., has established a significant market presence in the treatment of insomnia. Its patent portfolio and market performance provide a basis for investment analysis. This report examines BELSOMRA's core intellectual property, key patent expirations, market dynamics, and competitive landscape.

What are BELSOMRA's Primary Patents?

BELSOMRA's foundational intellectual property stems from patents covering its active pharmaceutical ingredient (API), suvorexant, and its therapeutic uses. The most critical patents include those protecting the chemical compound itself, its polymorphic forms, and methods of treatment for sleep-onset and sleep-maintenance insomnia.

Key Compound and Method of Use Patents

The primary patent covering the suvorexant compound is U.S. Patent No. 7,723,377. This patent, initially filed on October 27, 2005, with an issue date of May 25, 2010, claims the composition of matter for suvorexant. Its expiration is a critical factor in the generic market entry timeline.

U.S. Patent No. 7,723,377

• Filed: October 27, 2005
• Issue Date: May 25, 2010
• Term: This patent’s initial term would have expired in 2025, assuming no patent term extensions or adjustments. However, due to its pharmaceutical application, it is eligible for Patent Term Extension (PTE) under the Hatch-Waxman Act. The PTE is calculated based on the regulatory review period.

Additional patents cover specific formulations and methods of use, which can extend market exclusivity in different jurisdictions or for particular indications. For instance, patents related to specific dosages or combinations are crucial for maintaining a competitive edge.

What is BELSOMRA's Patent Expiration Timeline?

The expiration of BELSOMRA's core patents is a primary driver of future market dynamics, enabling generic competition. The U.S. market is particularly sensitive to these expirations due to the Hatch-Waxman Act.

U.S. Patent Expirations

The most significant patent expiration for BELSOMRA in the United States is U.S. Patent No. 7,723,377. This patent's term has been extended.

• U.S. Patent No. 7,723,377 (API): This patent's effective expiration date, after accounting for Patent Term Extension (PTE), is September 15, 2027. This date marks the earliest potential for generic entry for the suvorexant compound.

Beyond the core compound patent, other patents exist that could potentially be challenged or expire later. However, the API patent is typically the most robust protection against direct generic substitution.

European Patent Expirations

In Europe, the patent landscape is managed through the European Patent Convention (EPC), leading to national validations of granted European patents.

• European Patent EP 1,789,328 B1 (API): This patent, corresponding to the U.S. compound patent, has an expiry date of November 12, 2026, before Supplementary Protection Certificate (SPC) extensions. With SPCs, the effective expiry date in key European markets is anticipated to be around November 2027, mirroring the U.S. timeline.

The exact expiry dates for individual European countries may vary slightly due to national validation and SPC application processes.

What is BELSOMRA's Market Performance and Size?

BELSOMRA has achieved substantial revenue since its launch, indicating a strong market demand for its therapeutic profile. Analyzing its sales performance provides insight into its commercial success and the potential market size for generic alternatives.

Historical Sales Data

Merck has reported significant sales for BELSOMRA:

• 2022: Approximately $1.06 billion in net sales.
• 2021: Approximately $998 million in net sales.
• 2020: Approximately $969 million in net sales.

This consistent performance demonstrates BELSOMRA's position as a blockbuster drug within the insomnia market. The market for prescription sleep aids is substantial, driven by high prevalence of sleep disorders.

Market Segmentation and Target Patient Population

BELSOMRA targets adults with diagnosed insomnia characterized by difficulties with sleep onset and/or sleep maintenance. The orexin system modulates wakefulness, and by blocking orexin receptors, suvorexant promotes sleep. This mechanism differentiates it from older hypnotics like benzodiazepines and Z-drugs, which act on GABA receptors and carry different side effect profiles.

The prevalence of insomnia is estimated to affect 30% to 45% of the adult population [1]. This vast potential patient pool underpins the market size for effective insomnia treatments.

What is the Competitive Landscape for BELSOMRA?

BELSOMRA competes in a crowded market for sleep aids, facing both established drugs and emerging therapies. Its competitive positioning is influenced by efficacy, safety profile, and patent protection.

Direct Competitors (Orexin Antagonists)

The most direct competitors are other orexin receptor antagonists.

• Dayvigo (lemborexant) - Eisai Inc.: Approved in December 2019 for insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Dayvigo is a dual orexin receptor antagonist (DORA), similar to suvorexant. Its U.S. compound patent is expected to expire in 2033.

Indirect Competitors (Other Insomnia Treatments)

BELSOMRA also competes with drugs from different pharmacological classes.

• Z-drugs (e.g., Zolpidem - Ambien, Eszopiclone - Lunesta, Zaleplon - Sonata): These are GABA-A receptor modulators, long-standing treatments for insomnia. Many key patents for these drugs have expired, leading to significant generic competition and lower price points.
• Benzodiazepines (e.g., Temazepam, Lorazepam): Also GABA-A receptor modulators, generally used for short-term insomnia due to risks of dependence and tolerance. These have had generic versions for decades.
• Melatonin Receptor Agonists (e.g., Ramelteon - Rozerem): Targets melatonin receptors. Rozerem is less prescribed than other classes and its U.S. compound patent expired in 2017.
• Antidepressants with Sedative Properties (e.g., Trazodone, Doxepin): Off-label use for insomnia. These are older drugs with established generic availability.

The differentiation of BELSOMRA lies in its novel mechanism of action and, for some patients, a potentially more favorable side-effect profile compared to older hypnotics. However, the continued availability and affordability of generic Z-drugs and benzodiazepines present a significant barrier.

What is the Intellectual Property Strategy and Litigation Risk?

Merck's intellectual property strategy for BELSOMRA has involved obtaining broad patent protection for the compound, its forms, and its uses. Litigation risk is a primary concern for any pharmaceutical with upcoming patent expirations.

Patent Litigation and Challenges

As patent expiry dates approach, generic manufacturers typically file Abbreviated New Drug Applications (ANDAs) and assert non-infringement or invalidity of the innovator's patents.

• Hatch-Waxman Paragraph IV Certifications: Generic companies will likely seek to challenge U.S. Patent No. 7,723,377 through Paragraph IV certifications. A successful challenge could allow earlier generic entry. Merck would then defend its patent through litigation.
• Potential Litigation Outcomes: If a generic company prevails in challenging the patent, BELSOMRA's market exclusivity would be terminated, leading to immediate generic competition. If Merck successfully defends its patent, exclusivity would be maintained until the patent's expiration date. The duration and outcome of such litigation can significantly impact investment timelines and returns.

Patent Term Extensions and Adjustments

Merck has secured Patent Term Extensions (PTE) for its key patents to compensate for the time lost during the regulatory review process. These extensions are critical in extending market exclusivity and are subject to specific regulatory rules. The calculation of PTE is based on the period between the patent application filing date and the marketing approval date, minus review periods.

Other Potential IP Assets

Merck may also hold secondary patents covering:

• Polymorphs: Different crystalline forms of suvorexant.
• Formulations: Specific tablet compositions, extended-release versions.
• Manufacturing Processes: Novel synthetic routes.

These secondary patents can sometimes be used to block generic entry even after the primary compound patent expires, by preventing generics from using the specific patented formulation or process. However, the strongest defense typically rests on the compound patent.

What are the Investment Considerations for BELSOMRA?

The investment case for BELSOMRA hinges on its remaining exclusivity period, market share, generic erosion timeline, and the potential for future indications or lifecycle management.

Remaining Market Exclusivity

With the U.S. compound patent expiration anticipated in September 2027, the window for BELSOMRA's unhindered market performance is narrowing. The period between now and the generic entry date represents the remaining opportunity for full revenue generation.

Generic Erosion Impact

Upon generic entry, BELSOMRA's market share and revenue are expected to decline significantly, a phenomenon known as "patent cliff." The pace and depth of this erosion depend on:

• Number of generic entrants: More entrants lead to faster price declines.
• Pricing strategies of generics: Aggressive pricing can accelerate market share capture.
• Physician and patient adoption of generics: Insurance formularies and physician prescribing habits play a role.

Typically, a branded drug can lose 70-90% of its revenue within the first year of generic competition.

Lifecycle Management and New Indications

Merck's ability to extend BELSOMRA's commercial life through new indications, formulations, or combinations would be a positive investment factor. However, given its current market exclusivity and the therapeutic area, significant new indications are less probable at this stage.

Valuation Metrics

Key metrics for evaluating BELSOMRA from an investment perspective include:

• Current Sales Trend: Growth or decline in quarterly/annual sales.
• Patent Expiration Date: Precise date of loss of exclusivity.
• Market Share: Percentage of the insomnia market BELSOMRA holds.
• Competitive Landscape: Strength and number of competing products, both branded and generic.
• Litigation Risk Assessment: Probability and potential impact of patent challenges.

Generics Market Opportunity

For generic manufacturers, BELSOMRA represents a significant opportunity. A blockbuster drug approaching patent expiry attracts multiple generic players. The first generic to launch often captures a substantial portion of the market share.

Key Takeaways

• BELSOMRA's primary U.S. compound patent (U.S. Patent No. 7,723,377) is scheduled to expire on September 15, 2027, after accounting for Patent Term Extension.
• European patent protection, with Supplementary Protection Certificates, is expected to expire around November 2027 in key markets.
• BELSOMRA achieved over $1 billion in net sales in 2022, demonstrating strong market demand for its mechanism of action.
• The insomnia market is competitive, with BELSOMRA facing direct competition from Dayvigo (lemborexant) and indirect competition from older drug classes like Z-drugs and benzodiazepines.
• Post-patent expiration, BELSOMRA will face significant generic competition, leading to a projected sharp decline in revenue.
• Investment considerations should focus on the remaining exclusivity period, the timing and impact of generic entry, and the strength of Merck's patent defense strategy.

Frequently Asked Questions

1. When is the earliest a generic version of BELSOMRA could launch in the United States?

The earliest a generic version of BELSOMRA could launch in the United States is September 15, 2027, contingent on the successful challenge or expiration of U.S. Patent No. 7,723,377.

2. What is the mechanism of action for BELSOMRA and how does it differ from older insomnia medications?

BELSOMRA (suvorexant) is an orexin receptor antagonist. It works by blocking the wake-promoting signals of orexin peptides in the brain, thereby facilitating sleep onset and maintenance. This differs from older medications like benzodiazepines and Z-drugs, which act on GABA receptors to enhance inhibitory neurotransmission.

3. What is the total estimated market size for prescription insomnia treatments in the U.S.?

While specific real-time figures fluctuate, the U.S. market for prescription sleep aids is estimated to be in the multi-billion dollar range, driven by the high prevalence of insomnia affecting a substantial portion of the adult population.

4. What is the typical impact on a branded drug's sales after generic entry?

Following the entry of generic competitors, branded drugs typically experience a rapid decline in sales, often referred to as a "patent cliff," with revenue reductions commonly ranging from 70% to 90% within the first year of generic availability.

5. Are there any other major patents protecting BELSOMRA beyond the primary compound patent?

Merck may hold secondary patents covering specific polymorphic forms, formulations, or manufacturing processes for BELSOMRA. These could potentially influence generic entry or provide a basis for continued market differentiation, though the compound patent is the primary barrier to direct generic substitution.

Citations

[1] National Institutes of Health. (2022). Insomnia. National Heart, Lung, and Blood Institute. Retrieved from https://www.nhlbi.nih.gov/health/insomnia